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INTRODUCTION AND OBJECTIVES
The technique is based on the administration of a photosensitizing or pro-drug agent, which accumulates preferentially in the
tumor tissue, and in the subsequent stimulation of the area to be treated by light of a suitable wavelength. This will initiate a
photochemical process that leads directly to the destruction of the tumor cells, and indirectly causes a deterioration of the tumoral
vasculature.
vThe aim of this bibliographical review is to describe and synthesize the basic principles of photodynamic therapy (PDT), to give
special emphasis to its materials and clinical applications, to make a comparison of its uses in different species.
The three main processes by which reactive oxygen
species (ROS) contribute to tumor destruction using
PDT are:
1. Direct cell damage.
2. Indirectly, due to vascular collapse.
3. Activation of immune responses against tumor cells.
ADVERSE EFFECTS
These are not very common.
Recent studies have shown that the main adverse effects of
patients after treatment with PDT are hyperemia, edema,
cyanosis, exudation, crusting and immunosuppression.
MECANISM OF ACTION
Cat, male, 6 years. PDT treatment against SCC in UAB Veterinary Hospital.
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CONCLUSIONS
PDT offers great potential and may be useful as a
complement, in a bimodal therapy, or a good alternative to
certain therapies for some types of tumors in veterinary
oncology. Even so, it is necessary to continue investigating
and developing new photosensitizers and lasers to
decrease costs and improve their results.
Picture modified from Wachowska et al. 2011.
• LEDs
• Diode lasers
There is not established dose of light in 
PDT.  Usually between 600- 800 nm
MAIN USES IN TUMORS
Ø Squamous cell carcinoma (SCC) in cats, dogs and
horses.
Ø Equine sarcoids.
Ø Basal cell carcinomas (humans).
OTHER USE
Infections like leishmania, palliative treatments, keratosis,
macular degeneration related to age, diagnostic method to
verify that the margins remain free of neoplastic tissue after
an intervention…
Can be administered  
systemically (PO or IV) or 
topically.
ALA, mTHP, HPPH, MAL…
SPECIES CASES OUTCOME REFERENCES
Feline
149 Squamous cell carcinomas 
(SCC):  nose, ear, eyelid and face.
Response ratio: 62-100%.
Recurrence rate: 20-63%
Mean time of recurrence: 129 days
(Stell et al. 2001)
Equine 19 Sarcoid 
Response ratio: 72-93%
Recurrence rate: 39% (Gustafson et al. 2004)
Equine
10 Squamous cell carcinomas 
(SCC): periocular
Response ratio: 100%
Recurrence rate after 25 months: 0%
(Giuliano et al. 2014)
Human 330 basal cell carcinomas 
(BCC) 
Response ratio: 92% in superficial BCC and 
71% in nodular (Zeitouni et al. 2001)
Human Kaposi’s Sarcoma
(1 patient) 
Complete response after 5 treatments with 
PDT. (Tardivo et al. 2006)
Canine 11 oral squamous cell 
carcinomas
Response ratio: 72%
Recurrence ratio: 18% 
(McCaw et al. 2000)
